News and Media

More On Colucid

Phase 2b Proof of Concept

Lasmiditan SP-Agreement

IV Lasmiditan Phase 2 Proof of Concept

By the Numbers

More than 36 Million Americans have migraines.

That's 12% of the adult population.

Learn More About the Numbers

About Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds.

Learn More About CoLucid